Alanazi, N.; Siyal, A.; Basit, S.; Shammas, M.; Al-Mukhaylid, S.; Aleem, A.; Mahmood, A.; Iqbal, Z.
Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case–Control Study. Hematol. Rep. 2024, 16, 465-478.
https://doi.org/10.3390/hematolrep16030045
AMA Style
Alanazi N, Siyal A, Basit S, Shammas M, Al-Mukhaylid S, Aleem A, Mahmood A, Iqbal Z.
Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case–Control Study. Hematology Reports. 2024; 16(3):465-478.
https://doi.org/10.3390/hematolrep16030045
Chicago/Turabian Style
Alanazi, Nawaf, Abdulaziz Siyal, Sulman Basit, Masood Shammas, Sarah Al-Mukhaylid, Aamer Aleem, Amer Mahmood, and Zafar Iqbal.
2024. "Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case–Control Study" Hematology Reports 16, no. 3: 465-478.
https://doi.org/10.3390/hematolrep16030045
APA Style
Alanazi, N., Siyal, A., Basit, S., Shammas, M., Al-Mukhaylid, S., Aleem, A., Mahmood, A., & Iqbal, Z.
(2024). Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case–Control Study. Hematology Reports, 16(3), 465-478.
https://doi.org/10.3390/hematolrep16030045
